Women across the United States who used Depo-Provera for years are now being diagnosed with brain tumors called meningiomas. Recent medical studies have found a link between long-term use of this popular birth control shot and increased risk of these tumors.
The findings have prompted the FDA to update its safety warnings and led to thousands of lawsuits from women who say they were never warned about this risk.
If you or someone you care about used Depo-Provera for an extended period and later developed a brain tumor, understanding the medical evidence and your legal options matters.
Prior results do not guarantee a similar outcome.
What Is Depo-Provera and How Does It Work?
Depo-Provera is an injectable birth control shot containing medroxyprogesterone acetate, a synthetic form of the hormone progesterone. Women receive the injection every three months to prevent pregnancy. The medication works by stopping ovulation and changing the cervical mucus and uterine lining.
Millions of women have used Depo-Provera since its approval decades ago. Many chose it because of the convenience of quarterly injections rather than daily pills.
Healthcare providers often recommended it as a reliable contraceptive option, particularly for women who had difficulty remembering to take daily medication.
The concern is that medroxyprogesterone acetate does not just affect reproductive organs.
This synthetic hormone can act on progesterone receptors throughout the body, including in the protective membranes covering the brain and spinal cord. Those membranes, called the meninges, are exactly where meningiomas develop.
What Are Meningiomas and Why Do They Matter?
A meningioma is a tumor that grows from the meninges, the layers of tissue that cover your brain and spinal cord. Most meningiomas grow slowly and are technically benign, meaning they are not cancerous in the traditional sense. But calling them benign does not mean they are harmless.
When a tumor grows inside your skull, even a slow-growing one, it can cause serious problems. The brain sits in a confined space with no room for extra mass. As a meningioma grows, it can press on brain tissue, blood vessels, and nerves. The location of the tumor determines what symptoms develop and how serious it becomes.
Many meningiomas express progesterone receptors on their surface, meaning they respond to progesterone and synthetic progestins like the medroxyprogesterone in Depo-Provera.
Scientists have long suspected that prolonged exposure to these hormones might encourage meningioma growth in susceptible individuals. Recent research has turned that suspicion into documented evidence.
What Symptoms Should Former Depo-Provera Users Watch For?
Meningiomas often grow so slowly that symptoms develop gradually over months or even years. Many women dismiss early warning signs as stress, aging, or unrelated health issues. But if you used Depo-Provera for an extended period, the following symptoms deserve prompt medical attention:
Persistent, worsening headaches. Not ordinary tension headaches that come and go, but headaches that grow more frequent, more severe, or different in character than anything experienced before, sometimes waking a person at night or worsening when lying down.
Vision changes. Blurred vision, double vision, or loss of peripheral vision, which can show up as bumping into things on one side or trouble judging distances while driving.
Seizures. These can occur even without a prior history of epilepsy. They may appear as full convulsions, or as brief episodes of confusion, staring spells, or involuntary movements of one part of the body.
Weakness or numbness on one side of the body. This suggests the tumor is affecting motor or sensory areas of the brain. Balance and coordination problems can also develop if the tumor grows near the cerebellum.
Cognitive or personality changes. Memory problems, difficulty concentrating, confusion, or changes in mood and behavior, including new irritability, depression, or anxiety, or losing interest in activities once enjoyed. Family members often notice these changes before the affected person does.
These symptoms do not automatically mean you have a meningioma. Many other conditions can cause similar problems.
What Does the Medical Research Actually Show?
Multiple large studies published between 2024 and 2025 have documented a link between Depo-Provera and meningiomas. T
A major study published in the British Medical Journal in 2024 examined French women who underwent surgery for intracranial meningiomas, comparing their contraceptive histories to women without meningiomas.
Women who used injectable medroxyprogesterone acetate for one year or longer had about 5.5 times the risk of developing a meningioma compared to non-users. Women who used Depo-Provera for less than a year did not show the same elevated risk.
In 2025, researchers published findings in JAMA Neurology drawn from a U.S. health research database covering more than 10 million patient records.
Comparing women who used the Depo-Provera injection to women who did not, they found that users had 2.43 times the risk of a meningioma diagnosis. The risk was highest among women who used the drug for more than four years or who started using it after age 31.
A Swedish registry study published in Neuro-Oncology reported an odds ratio of 5.49 for meningioma among users of contraceptives containing medroxyprogesterone.
This reinforced the findings from France and the United States, showing the association holds across different populations and healthcare systems.
What Did the FDA Do About This Information?
In December 2025, the Food and Drug Administration approved updated labeling for Depo-Provera and Depo-SubQ Provera 104 that explicitly warns about meningioma risk.
The updated label states that meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use.
The new labeling instructs healthcare providers to monitor patients using these products for signs and symptoms of meningioma. If a meningioma is diagnosed, the label now says to discontinue Depo-Provera.
This label change is significant for several reasons.
First, it represents official acknowledgment by the FDA that the risk is real and serious enough to warrant explicit warnings.
Second, it changes the standard of care going forward. Healthcare providers who prescribe Depo-Provera now have a regulatory obligation to discuss meningioma risk with patients and monitor for symptoms.
But the timing of this warning matters enormously to women already diagnosed with meningiomas. Many used Depo-Provera for years before these warnings existed.
They made their contraceptive choices without knowing about brain tumor risk, and their doctors prescribed the medication without being able to warn them. This is central to the failure-to-warn allegations in current lawsuits.
Can You Take Legal Action If You Developed a Meningioma After Using Depo-Provera?
Women diagnosed with meningiomas after long-term Depo-Provera use have filed lawsuits against the manufacturer.
These claims generally fall under New York’s laws covering defective prescription drugs, including failure-to-warn theories, design defect allegations arguing that safer contraceptive alternatives existed, negligence in researching and monitoring the drug’s safety profile, and breach of warranty regarding the product’s safety.
In February 2025, federal courts consolidated meningioma claims against the Depo-Provera manufacturer into a multidistrict litigation, or MDL. This MDL structure allows similar cases from across the country to be managed together for pretrial proceedings, discovery, and coordinated expert evidence.
Individual plaintiffs maintain their own cases and potential outcomes, but core questions about whether Depo-Provera causes meningiomas and whether the manufacturer provided adequate warnings are litigated in a coordinated way.
The number of cases has grown rapidly from a few dozen initial filings to thousands of claims within about a year.
What Kind of Damages Can Meningioma Patients Recover?
Women who develop meningiomas after using Depo-Provera often face substantial medical expenses. Brain imaging including MRI and CT scans, consultations with neurologists and neurosurgeons, the surgery itself, hospitalization, and rehabilitation all generate significant bills.
Many patients need ongoing monitoring with periodic brain scans to watch for tumor recurrence. Some require additional surgeries if the tumor grows back. Medications to control seizures, manage pain, or address other symptoms add to the costs.
Lost income and diminished earning capacity represent another major category of damages. Brain surgery requires weeks or months of recovery, and some patients cannot return to their previous work due to cognitive impairment, seizure disorders, or other lasting neurological problems.
Family members may also have claims for loss of consortium, recognizing how illness and treatment affect marital relationships and family life.
How Does New York Law Apply to These Cases?
While the Depo-Provera litigation is organized as a federal multidistrict litigation, New York residents who were injured can participate. New York has its own product liability laws and statutes of limitations that may affect your case.
New York generally allows injured patients to bring claims based on design defects, manufacturing defects, and failure to warn.
For prescription drugs, failure-to-warn claims focus on whether the manufacturer provided adequate information to prescribing physicians.
New York’s statute of limitations for a personal injury claim based on a defective drug is generally three years under CPLR 214(5). Because meningiomas often develop years after Depo-Provera use and aren’t always immediately linked to the drug, New York’s discovery rule for latent injuries can apply.
Under CPLR 214-c, when an injury is caused by the latent effects of exposure to a substance introduced into the body, the three-year period runs from the date the injury was discovered, or reasonably should have been discovered, rather than from the date of exposure. N
ew York courts have interpreted this discovery rule narrowly, so whether it extends your filing deadline depends on the specific facts of your diagnosis and medical history.
An attorney familiar with both New York law and the federal MDL structure can help you understand how these frameworks apply to your specific situation.
Frequently Asked Questions
How long do I have to file a Depo-Provera lawsuit in New York?
New York generally requires a personal injury claim to be filed within three years under CPLR 214(5). Because meningiomas can develop years after exposure, a discovery-rule exception may extend this deadline in some cases. Whether it applies depends on when your tumor was diagnosed and when it could reasonably have been connected to Depo-Provera use, so it’s worth discussing your specific timeline with an attorney.
Do I need to have used Depo-Provera for a specific length of time to have a claim?
The research showing increased meningioma risk has focused on women who used Depo-Provera for a year or longer, with risk generally rising the longer someone used it. Short-term use has not shown the same association in the available studies. Whether a shorter period of use supports a claim depends on your individual medical history and exposure timeline.
What is the Depo-Provera multidistrict litigation and does it affect my individual case?
The multidistrict litigation, or MDL, consolidates federal Depo-Provera meningioma cases before one court for shared pretrial proceedings like discovery and expert evidence. It is not a class action. Each plaintiff’s case is evaluated on its own facts and outcome, even though the cases share common questions about the drug and the manufacturer’s warnings.
What medical records do I need to support a Depo-Provera meningioma claim?
Useful records typically include documentation of your Depo-Provera injection history and dates, imaging studies showing the tumor, pathology reports from any biopsy or surgery, and records of related symptoms, treatment, and expenses. An attorney can help you identify and request records you may not already have on hand.
Can I still take legal action if my meningioma was treated years ago?
It’s possible, depending on when you were diagnosed and when the connection to Depo-Provera could reasonably have been discovered. Because deadlines and eligibility can be affected by ongoing developments in the litigation, it’s worth having your specific timeline reviewed rather than assuming too much time has passed.
Summing it Up
The connection between long-term Depo-Provera use and meningiomas is no longer speculative. Multiple studies across different countries have documented increased risk, the FDA updated its labeling in December 2025 to warn about it, and thousands of women have filed claims describing brain tumors after years of using the contraceptive.
If you developed a meningioma after using Depo-Provera, call 833-PORTER9, email info@porterlawteam.com, or reach us through our contact page to talk through your situation. Prior results do not guarantee a similar outcome.
This article is for informational and educational purposes only. It is not a substitute for medical advice from a qualified healthcare provider or legal advice based on your specific circumstances.
